Pharmacopsychiatry
Journal Impact IF - Analysis · Trend · Prediction · Ranking


New

Journal Impact IF

2019-2020

4.34

58.5%

Journal Impact IF Trend

Related Journals

Popular Journals

Pharmacopsychiatry

The 2019-2020 Journal Impact IF of Pharmacopsychiatry is 4.34, which is just updated in 2020.

Pharmacopsychiatry Impact Factor
Highest IF
4.34
Highest Journal Impact IF

The highest Journal Impact IF of Pharmacopsychiatry is 4.34.

Lowest IF
1.474
Lowest Journal Impact IF

The lowest Journal Impact IF of Pharmacopsychiatry is 1.474.

Total Growth Rate
109.6%
IF Total Growth Rate

The total growth rate of Pharmacopsychiatry IF is 109.6%.

Annual Growth Rate
12.2%
IF Annual Growth Rate

The annual growth rate of Pharmacopsychiatry IF is 12.2%.

Journal Impact IF Ranking

Subcategory Quartile Rank Percentile
Psychiatry and Mental Health Q1 83/506

Psychiatry and Mental Health 83%

Pharmacology (medical) Q1 52/237

Pharmacology (medical) 78%

Journal Impact IF Ranking

· In the Psychiatry and Mental Health research field, the Quartile of Pharmacopsychiatry is Q1. Pharmacopsychiatry has been ranked #83 over 506 related journals in the Psychiatry and Mental Health research category. The ranking percentile of Pharmacopsychiatry is around 83% in the field of Psychiatry and Mental Health.
· In the Pharmacology (medical) research field, the Quartile of Pharmacopsychiatry is Q1. Pharmacopsychiatry has been ranked #52 over 237 related journals in the Pharmacology (medical) research category. The ranking percentile of Pharmacopsychiatry is around 78% in the field of Pharmacology (medical).

Pharmacopsychiatry Impact Factor 2020-2021 Prediction

Pharmacopsychiatry Impact Factor Predition System

Pharmacopsychiatry Impact Factor Prediction System is now online. You can start share your valuable insights with the community.

Predict Check All Preditions
Total Publications
4682
Total Citations
75032

Annual Publication Volume

Annual Citation Record

International Collaboration Trend

Cited Documents Trend

Journal Impact IF History

Year Journal Impact IF
Year Journal Impact IF
2019-2020 4.34
2018-2019 2.738
2017-2018 2.064
2016-2017 1.765
2015-2016 1.474
2014-2015 1.851
2013-2014 2.168
2012-2013 2.109
2011-2012 2.071
Journal Impact IF History

· The 2019-2020 Journal Impact IF of Pharmacopsychiatry is 4.34
· The 2018-2019 Journal Impact IF of Pharmacopsychiatry is 2.738
· The 2017-2018 Journal Impact IF of Pharmacopsychiatry is 2.064
· The 2016-2017 Journal Impact IF of Pharmacopsychiatry is 1.765
· The 2015-2016 Journal Impact IF of Pharmacopsychiatry is 1.474
· The 2014-2015 Journal Impact IF of Pharmacopsychiatry is 1.851
· The 2013-2014 Journal Impact IF of Pharmacopsychiatry is 2.168
· The 2012-2013 Journal Impact IF of Pharmacopsychiatry is 2.109
· The 2011-2012 Journal Impact IF of Pharmacopsychiatry is 2.071

Publications Cites Dataset

Year Publications Citations
Year Publications Citations
1968 24 2
1969 28 13
1970 26 33
1971 36 54
1972 29 92
1973 33 108
1974 41 132
1975 33 155
1976 38 165
1977 48 225
1978 32 288
1979 51 317
1980 32 424
1981 37 344
1982 49 429
1983 39 523
1984 41 468
1985 110 418
1986 142 585
1987 66 577
1988 144 697
1989 66 638
1990 92 895
1991 53 889
1992 60 904
1993 45 966
1994 67 891
1995 52 913
1996 37 961
1997 69 1128
1998 72 1336
1999 55 1573
2000 55 1904
2001 75 1933
2002 67 2219
2003 88 2493
2004 431 2367
2005 412 3056
2006 80 3092
2007 303 2938
2008 119 2976
2009 263 3083
2010 83 3045
2011 199 3274
2012 111 3293
2013 140 3276
2014 88 3329
2015 127 2907
2016 87 2745
2017 67 2715
2018 38 2104
2019 50 2231
2020 46 2630
2021 6 279
Publications Cites Dataset

· The Pharmacopsychiatry has published 24 reports and received 2 citations in 1968.
· The Pharmacopsychiatry has published 28 reports and received 13 citations in 1969.
· The Pharmacopsychiatry has published 26 reports and received 33 citations in 1970.
· The Pharmacopsychiatry has published 36 reports and received 54 citations in 1971.
· The Pharmacopsychiatry has published 29 reports and received 92 citations in 1972.
· The Pharmacopsychiatry has published 33 reports and received 108 citations in 1973.
· The Pharmacopsychiatry has published 41 reports and received 132 citations in 1974.
· The Pharmacopsychiatry has published 33 reports and received 155 citations in 1975.
· The Pharmacopsychiatry has published 38 reports and received 165 citations in 1976.
· The Pharmacopsychiatry has published 48 reports and received 225 citations in 1977.
· The Pharmacopsychiatry has published 32 reports and received 288 citations in 1978.
· The Pharmacopsychiatry has published 51 reports and received 317 citations in 1979.
· The Pharmacopsychiatry has published 32 reports and received 424 citations in 1980.
· The Pharmacopsychiatry has published 37 reports and received 344 citations in 1981.
· The Pharmacopsychiatry has published 49 reports and received 429 citations in 1982.
· The Pharmacopsychiatry has published 39 reports and received 523 citations in 1983.
· The Pharmacopsychiatry has published 41 reports and received 468 citations in 1984.
· The Pharmacopsychiatry has published 110 reports and received 418 citations in 1985.
· The Pharmacopsychiatry has published 142 reports and received 585 citations in 1986.
· The Pharmacopsychiatry has published 66 reports and received 577 citations in 1987.
· The Pharmacopsychiatry has published 144 reports and received 697 citations in 1988.
· The Pharmacopsychiatry has published 66 reports and received 638 citations in 1989.
· The Pharmacopsychiatry has published 92 reports and received 895 citations in 1990.
· The Pharmacopsychiatry has published 53 reports and received 889 citations in 1991.
· The Pharmacopsychiatry has published 60 reports and received 904 citations in 1992.
· The Pharmacopsychiatry has published 45 reports and received 966 citations in 1993.
· The Pharmacopsychiatry has published 67 reports and received 891 citations in 1994.
· The Pharmacopsychiatry has published 52 reports and received 913 citations in 1995.
· The Pharmacopsychiatry has published 37 reports and received 961 citations in 1996.
· The Pharmacopsychiatry has published 69 reports and received 1128 citations in 1997.
· The Pharmacopsychiatry has published 72 reports and received 1336 citations in 1998.
· The Pharmacopsychiatry has published 55 reports and received 1573 citations in 1999.
· The Pharmacopsychiatry has published 55 reports and received 1904 citations in 2000.
· The Pharmacopsychiatry has published 75 reports and received 1933 citations in 2001.
· The Pharmacopsychiatry has published 67 reports and received 2219 citations in 2002.
· The Pharmacopsychiatry has published 88 reports and received 2493 citations in 2003.
· The Pharmacopsychiatry has published 431 reports and received 2367 citations in 2004.
· The Pharmacopsychiatry has published 412 reports and received 3056 citations in 2005.
· The Pharmacopsychiatry has published 80 reports and received 3092 citations in 2006.
· The Pharmacopsychiatry has published 303 reports and received 2938 citations in 2007.
· The Pharmacopsychiatry has published 119 reports and received 2976 citations in 2008.
· The Pharmacopsychiatry has published 263 reports and received 3083 citations in 2009.
· The Pharmacopsychiatry has published 83 reports and received 3045 citations in 2010.
· The Pharmacopsychiatry has published 199 reports and received 3274 citations in 2011.
· The Pharmacopsychiatry has published 111 reports and received 3293 citations in 2012.
· The Pharmacopsychiatry has published 140 reports and received 3276 citations in 2013.
· The Pharmacopsychiatry has published 88 reports and received 3329 citations in 2014.
· The Pharmacopsychiatry has published 127 reports and received 2907 citations in 2015.
· The Pharmacopsychiatry has published 87 reports and received 2745 citations in 2016.
· The Pharmacopsychiatry has published 67 reports and received 2715 citations in 2017.
· The Pharmacopsychiatry has published 38 reports and received 2104 citations in 2018.
· The Pharmacopsychiatry has published 50 reports and received 2231 citations in 2019.
· The Pharmacopsychiatry has published 46 reports and received 2630 citations in 2020.
· The Pharmacopsychiatry has published 6 reports and received 279 citations in 2021.
· The total publications of Pharmacopsychiatry is 4682.
· The total citations of Pharmacopsychiatry is 75032.

What is Impact Factor?

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly average number of citations of articles published in the last two years in a given journal. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are often deemed to be more important, or carry more intrinsic prestige in their respective fields, than those with lower values.

Pharmacopsychiatry | Academic Accelerator - About the Impact Factor

Impact factor is commonly used to evaluate the relative importance of a journal within its field and to measure the frequency with which the “average article” in a journal has been cited in a particular time period. Journal which publishes more review articles will get highest IFs. Journals with higher IFs believed to be more important than those with lower ones. According to Eugene Garfield “impact simply reflects the ability of the journals and editors to attract the best paper available.” Journal which publishes more review articles will get maximum IFs. The Impact Factor of an academic journal is a scientometric Metric that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a Metric for the relative importance of a journal within its field; journals with higher Impact Factor are often deemed to be more important than those with lower ones. The Pharmacopsychiatry Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the Pharmacopsychiatry during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; they cannot be calculated until all of the 2020 publications have been processed by the indexing agency. New journals, which are indexed from their first published issue, will receive an impact factor after two years of indexing; in this case, the citations to the year prior to Volume 1, and the number of articles published in the year prior to Volume 1, are known zero values. Journals that are indexed starting with a volume other than the first volume will not get an impact factor until they have been indexed for three years. Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. In addition to the 2-year Impact Factor, the 3-year Impact Factor, 4-year Impact Factor, 5-year Impact Factor, Real-Time Impact Factor can provide further insights and factors into the impact of Pharmacopsychiatry.

History

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI). Impact factors are calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson ISI was sold to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.

Use

The impact factor is used to compare different journals within a certain field. The Web of Science indexes more than 11,500 science and social science journals. Journal impact factors are often used to evaluate the merit of individual articles and individual researchers. This use of impact factors was summarised by Hoeffel:

Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary.

Eugene Garfield

In brief, Impact factors may be used by:
  • Authors to decide where to submit an article for publication.
  • Libraries to make collection development decisions
  • Academic departments to assess academic productivity
  • Academic departments to make decisions on promotion and tenure.
As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Garfield agrees with Hoeffel,but warns about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Other things to consider about Impact Factors:
  • Many journals do not have an impact factor.
  • The impact factor cannot assess the quality of individual articles. Even if citations were evenly distributed among articles, the impact factor would only measure the interests of other researchers in an article, not its importance and usefulness.
  • Only research articles, technical notes and reviews are “citable” items. Editorials, letters, news items and meeting abstracts are “non-citable items”.
  • Only a small percentage of articles are highly cited and they are found in a small subset of journals. This small proportion accounts for a large percentage of citations.
  • Controversial papers, such as those based on fraudulent data, may be highly cited, distorting the impact factor of a journal.
  • Citation bias may exist. For example, English language resources may be favoured. Authors may cite their own work.
Moreover, informed and careful use of these impact data is essential, and should be based on a thorough understanding of the methodology used to generate impact factors. There are controversial aspects of using impact factors:
  • It is not clear whether the number of times a paper is cited measures its actual quality.
  • Some databases that calculate impact factors fail to incorporate publications including textbooks, handbooks and reference books.
  • Certain disciplines have low numbers of journals and usage. Therefore, one should only compare journals or researchers within the same discipline.
  • Review articles normally are cited more often and therefore can skew results.
  • Self-citing may also skew results.
  • Some resources used to calculate impact factors have inadequate international coverage.
  • Editorial policies can artificially inflate an impact factor.
Impact factors have often been used in advancement and tenure decision-making. Many recognize that this is a coarse tool for such important decisions, and that a multitude of factors should be taken into account in these deliberations. When considering the use of the impact factor (IF), keep these aspects in mind:
  • IF analysis is limited to citations from the journals indexed by the Web of Science/Web of Knowledge. Currently, the Web of Science indexes only 8621 journals across the full breadth of the sciences, and just 3121 in the social sciences.
  • A high IF/citation rate says nothing about the quality -- or even, validity -- of the references being cited. Notorious or even retracted articles often attract a lot of attention, hence a high number of citations. The notority related to the first publication on "cold fusion" is one such example.
  • Journals that publish more "review articles" are often found near the top of the rankings. While not known for publishing new, creative findings, these individual articles tend to be heavily cited.
  • The IF measures the average number of citations to articles in the journal -- given this, a small number of highly-cited articles will skew the figure.
  • It takes several years for new journals to be added to the list of titles indexed by the Web of Science/Web of Knowledge, so these newer titles will be under-represented.
  • It's alleged that journal editors have learned to "game" the system, encouraging authors to cite their works previously published in the same journal.
Comparing Journals Across Disciplines? Not a good idea! Using Impact Factors within a given discipline should only be done with great care, as described above. Using impact factor data to compare journals across disciplines is even more problematic. Here are some of the reasons:
  • Disciplines where older literature is still referenced, such as Chemistry and Mathematics, offer challenges to the methodolgy since older citations (older than two years) are not used to calculate the impact factor for a given journal. (Five-year impact factor analysis, which can be calculated using the Journal Citation Index database, helps smooth out this problem only to some degree.)
  • Different disciplines have different practices regarding tendency to cite larger numbers of references. Higher overall citation rates will bump upward impact factor measurements.
  • Where it's common for large numbers of authors to collaborate on a single paper, such as in Physics, the tendency of authors to cite themselves (and in this case, more authors) will result in increased citation rates.

Pros and Cons of the Impact Factor

Pros:

  • A vetted, established metric for measuring journal impact within a discipline.
  • Designed to eliminate bias based on journal size and frequency.
Cons:
  • Individual articles makes an uneven contribution to overall Impact Factor.
  • Impact Factor does not account for certain things, things like context (postive or negative citaion) and intentionality (self-citation).
  • The metric is proprietary to and bound by the contents of the Thomson Reuters database.
  • Citations, on which the Impact Factor is based, count for less than 1% of an article's overall use.

Criticism

Numerous critiques have been made regarding the use of impact factors. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on behavior of scholars, editors and other stakeholders. Others have made more general criticisms, arguing that emphasis on impact factor results from negative influence of neoliberal policies on academia claiming that what is needed is not just replacement of the impact factor with more sophisticated metrics for science publications but also discussion on the social value of research assessment and the growing precariousness of scientific careers in higher education.
Experts stress that there are limitations in using impact factors to evaluate a scholar's work. There are many reasons cited for not relying on impact factor alone to evaluate the output of a particular individual. Among these are the following:

  • A single factor is not sufficient for evaluating an author's work.
  • Journal values are meaningless unless compared within the same discipline. Impact factors vary among disciplines.
  • The impact factor was originally devised to show the impact of a specific journal, not a specific scholar. The quality and impact of the author's work may extend beyond the impact of a particular journal.
According to Jim Testa, a researcher for ThomsonReuters Scientific, the most widespread misuse of the Impact Factor is to evaluate the work of an individual author (instead of a journal). "To say that because a researcher is publishing in a certain journal, he or she is more influential or deserves more credit is not necessarily true. There are many other variables to consider." (interview 6/26/2008 in Thomson Reuters blog entry)

Pharmacopsychiatry
Journal Profile

About

Covering advances in the fi eld of psychotropic drugs, Pharmaco psychiatry provides psychiatrists, neuroscientists and clinicians with key clinical insights and describes new avenues of research and treatment. The pharmacological and neurobiological bases of psychiatric disorders are discussed by presenting clinical and experimental research. None

Highly Cited Keywords

ISSN
0176-3679
ISSN

The ISSN of Pharmacopsychiatry is 0176-3679 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

ISSN (Online)
1439-0795
ISSN (Online)

The ISSN (Online) of Pharmacopsychiatry is 1439-0795 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

Publisher
Georg Thieme Verlag
Publisher

Pharmacopsychiatry is published by Georg Thieme Verlag .

Publication Frequency
-
Publication Frequency

Pharmacopsychiatry publishes reports - .

Coverage
1984 - Present
Coverage

The Publication History of Pharmacopsychiatry covers 1984 - Present .

Open Access
NO
Open Access

Pharmacopsychiatry is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers.

Publication Fee
Publication Fee

There is no publication fee for submiting manuscript to Pharmacopsychiatry. Pharmacopsychiatry is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles.

Language
-
Language

The language of Pharmacopsychiatry is - .

Country/Region
Germany
Country/Region

The publisher of Pharmacopsychiatry is Georg Thieme Verlag , which locates in Germany .

Selected Articles

Full Title Authors
Full Title Authors
Studies of Half-Lives of Long-Acting Antipsychotics are Needed Georgios Schoretsanitis · Alejandro G. Villasante-Tezanos · Jose de Leon · Jose de Leon
TDM in inpatient, outpatient and general practice settings: similarities, differences, benefits, limits G Gründer · G Gründer
Evaluation of Myocardial Damage After Electroconvulsive Therapy: Analyses of High-Sensitive Cardiac Troponin I and N-Terminal pro-B-type Natriuretic Peptide Laura Kranaster · Johanna Badstübner · Suna Su Aksay · Jan Malte Bumb · Rayan Suliman · Michael Neumaier · Alexander Sartorius · Alexander Sartorius
Efficacy and Effectiveness of Lithium in the Long-Term Treatment of Bipolar Disorders: An Update 2018 Emanuel Severus · Michael Bauer · John Geddes · John Geddes
Happy 50th Anniversary, Lithium Clinics: The Perspective of a Long-Time User Marylou Selo · Marylou Selo
Comprehensive measurements of intrauterine and postnatal exposure to lamotrigine Michael Paulzen · Julia C. Stingl · Julia C. Stingl · Marc Augustin · Helena Saßmannshausen · Cordula Franz · G Gründer · Georgios Schoretsanitis · Georgios Schoretsanitis
Therapeutic Drug Monitoring in children and adolescents – looking 10 years back and forward K Egberts · Sy Dang · P Plener · A Karwautz · R Taurines · M Romanos · M Gerlach · M Gerlach
TDM of antiepileptic drugs in psychiatric patients Y Lipecki · Ekkehard Haen · Ekkehard Haen
Discrepancies Between Nomenclature and Indications of Psychotropics Fusaka Minami · Joseph Zohar · Takefumi Suzuki · Teruki Koizumi · Masaru Mimura · Gohei Yagi · Hiroyuki Uchida · Hiroyuki Uchida · Hiroyuki Uchida
Influence of saliva pH-value on the ratio of amphetamine saliva to serum concentration C Wohkittel · Marcel Romanos · P Högger · Manfred Gerlach · Manfred Gerlach
Drug interaction of methadone with oral contraceptive medication. Clinic, treatment and TDM I Adamovic · Ursula Havemann-Reinecke · Ursula Havemann-Reinecke
Therapeutic drug monitoring (TDM) and comorbidity T Messer · T Messer
Importance of antihypertensive drugs in psychiatry K Endres · Ekkehard Haen · Ekkehard Haen
Differences in the pharmacokinetics of psychopharmacological drugs between smokers and nonsmokers M Scherf-Clavel · L Samanski · R Burger · J. Deckert · A Menke · Stefan Unterecker · Stefan Unterecker
The effect of pharmacological interaction between a proton pump inhibitor pantoprazole and clozapine M Kuzin · Georgios Schoretsanitis · Ekkehard Haen · G Dammann · Christoph Hiemke · G Gründer · Michael Paulzen · Michael Paulzen
Asymmetric dimethylarginine in psychiatric disorders D Braun · J Schlossmann · Ekkehard Haen · Ekkehard Haen
Therapeutic Drug Monitoring of bupropion and its metabolites using UHPLC F Ridders · Ekkehard Haen · Ekkehard Haen
A Novel Study Design to Systematically Explore the Impact of Trial Methodology on Psychopharmacological Treatment Outcome in Patients with Depression Emanuel Severus · Cathrin Sauer · Michael Bauer · Michael J. Ostacher · Ion-George Anghelescu · Ion-George Anghelescu
Factors influencing citalopram steady-state serum concentrations K Köhr · Ekkehard Haen · Ekkehard Haen
Optimization of a combined therapeutic drug monitoring – pharmacogenetic (TDMPG) approach to explain subtherapeutic, therapeutic and supratherapeutic concentrations of neuropsychopharmacologic medications E Farbmacher · T Bregolin · Lm Friedrich · S Mechtcheriakov · A Kaufmann · A Hausmann · R Weiner · A Hofer · G Zernig · G Zernig
AMBEW; a software application for drug assessment in clinical practice E Herdt · M Klon · M Schwarz · B Fay · Ekkehard Haen · Ekkehard Haen
A model of sedative load based on the therapeutic reference range A Geiben · Ekkehard Haen · Ekkehard Haen
Therapeutic Drug Monitoring of escitalopram: Influence by age, gender, body weight, BMI, smoking, caffeine and comedication with a special focus on interactions with mirtazapine and statins D Wolf · Ekkehard Haen · Ekkehard Haen
LC-MS/MS as versatile tool in therapeutic drug monitoring G Zurek · G Zurek
Dose-related reference ranges for evaluation of individual pharmacokinetic characteristics in TDM Ekkehard Haen · K Ruf · N BenOmar · N BenOmar
Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study Susanne Englisch · Hanna Sophie Jung · Antje Lewien · Anna Becker · Ulrike Nowak · Hanna Braun · Sarah Eisenacher · Jascha Thiem · Andreas Meyer-Lindenberg · Mathias Zink · Mathias Zink · Mathias Zink
Antisuicidal Effects in Mood Disorders: Are They Unique to Lithium? Leonardo Tondo · Leonardo Tondo · Ross J. Baldessarini · Ross J. Baldessarini · Ross J. Baldessarini
Peripheral Oxytocin Predicts Higher-Level Social Cognition in Men Regardless of Empathy Quotient Lisa Deuse · Olga A. Wudarczyk · Lena Rademacher · Peter Kaleta · Wolfram Karges · Stella Kacheva · G Gründer · Sarah E. Lammertz · Sarah E. Lammertz
Comparative Efficacy and Safety of Antipsychotic Drugs for Tic Disorders: A Systematic Review and Bayesian Network Meta-Analysis Chunsong Yang · Zilong Hao · Lingli Zhang · Cairong Zhu · Ping Zhu · Qin Guo · Qin Guo
Genetics of Lithium Response in Bipolar Disorder Sergi Papiol · Thomas G. Schulze · Martin Alda · Martin Alda
Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials Taro Kishi · Yuki Matsui · Yuki Matsuda · Asuka Katsuki · Hikaru Hori · Hiroko Yanagimoto · Kenji Sanada · Kiichiro Morita · Reiji Yoshimura · Katsuhiko Hagi · Nakao Iwata · Nakao Iwata
Impact of Chronic Cannabis Use on Auditory Mismatch Negativity Generation in Schizophrenia Patients Patrik Roser · Patrik Roser · Eva-Maria Pichler · Benedikt Habermeyer · Wolfram Kawohl · Georg Juckel · Georg Juckel
Kampo, A Japanese Traditional Medicinal System for Psychiatric Conditions: A Narrative Review Laina Tatsumi · Takefumi Suzuki · Takefumi Suzuki · Kazuo Yamada · Masaru Mimura · Hiroyuki Uchida · Hiroyuki Uchida · Hiroyuki Uchida
Lithium Clinics in Berlin and Dresden: a 50-Year Experience Werner Felber · Michael Bauer · Ute Lewitzka · Bruno Müller-Oerlinghausen · Bruno Müller-Oerlinghausen
QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients Gudrun Hefner · Martina Hahn · Matthias Hohner · Sybille C. Roll · Ansgar Klimke · Christoph Hiemke · Christoph Hiemke
Sexual Dysfunction in Unmedicated Patients with Schizophrenia and in Healthy Controls Theresa Dembler-Stamm · Jana Fiebig · Andreas Heinz · Jürgen Gallinat · Jürgen Gallinat
70 Years of Research and 50 Years of Lithium Clinics: From Serendipity to Gold Standard in Mood Disorders Michael Bauer · Michael Bauer
Cognitive Deficits in Methamphetamine Users: How Strong is The Evidence? Lisa Proebstl · Felicia Kamp · Gabi Koller · Michael Soyka · Michael Soyka · Michael Soyka
Lithium and Renal Impairment: A Review on a Still Hot Topic René Ernst Nielsen · Lars Vedel Kessing · Willem A. Nolen · Rasmus Wentzer Licht · Rasmus Wentzer Licht
Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness Michael Bauer · A. John Rush · A. John Rush · A. John Rush · Roland Ricken · Maximilian Pilhatsch · Mazda Adli · Mazda Adli
Sertindole: EEG Analysis, Tolerability, and Clinical Efficacy Adam Kroc · Marta Dębicka · Aleksandra Wierzbicka · Lidia Wołkow · Wojciech Jernajczyk · Adam Wichniak · Adam Wichniak
Hypothalamic-Pituitary-Adrenocortical Axis Activity in Alcohol-Dependent Patients During Treatment with High-Dose Baclofen Olga Geisel · Ludwig Schlemm · Ludwig Schlemm · Rainer Hellweg · Klaus Wiedemann · Christian Müller · Christian Müller
Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimers Disease Philipp Hessmann · Richard Dodel · Erika Baum · M. Müller · Greta Paschke · Bernhard Kis · Jan Zeidler · Mike Klora · Jens-Peter Reese · Monika Balzer-Geldsetzer · Monika Balzer-Geldsetzer
Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials Wei Zheng · Qing-E Zhang · Dong-Bin Cai · Xin-Hu Yang · Gabor S. Ungvari · Chee H. Ng · Ren-Rong Wu · Yu-Tao Xiang · Yu-Tao Xiang
Intramuscular Testosterone Supplementation Ameliorates Depression in Hypogonadal Men: A Retrospective Study in an Outpatient Department Andrei Miclea · M Miclea · Maximilian Pistor · Katharina Stegmayer · Robert Hoepner · Robert Hoepner
Clozapine-Induced DRESS Syndrome: A Case Series From the AMSP Multicenter Drug Safety Surveillance Project B. Sanader · Renate Grohmann · P. Grötsch · T. Schumann · S. Toto · P. Fernando · S. Stübner · S. Stübner
Lithium: A Global Perspective Gin S. Malhi · Gin S. Malhi · Gin S. Malhi
What Does Antidepressant Drug level Monitoring Reveal About Outpatient Treatment and Patient Adherence Petr Šilhán · R. Urinovska · I. Kacirova · Martin Hyza · Milan Grundmann · Eva Ceskova · Eva Ceskova
Lithium Treatment in Children and Adolescents Anne Duffy · Paul Grof · Paul Grof
DNA Methylation Profiling in a Neuroblastoma Cell Line Exposed to the Antipsychotic Perospirone Yui Murata · Yui Murata · Miki Bundo · Miki Bundo · Fumiko Sunaga · Kiyoto Kasai · Kazuya Iwamoto · Kazuya Iwamoto · Kazuya Iwamoto
Fat Mass and Obesity-Related Gene Variants rs9939609 and rs7185735 are Associated with Second-Generation Antipsychotic-Induced Weight Gain Charlotte Schröder · Fabian Czerwensky · Stefan Leucht · Werner Steimer · Werner Steimer
Response to Lithium in Patients with Bipolar Disorder: What are Psychiatrists Experiences and Practices Compared to Literature Review? Claire Montlahuc · Diane Grillault Laroche · Gérald Bagoe · Bruno Etain · Frank Bellivier · Sylvie Chevret · Sylvie Chevret
Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study Konstantinos N. Fountoulakis · Vangelis Karavelas · Stefania Moysidou · Dimitris Mavridis · Konstantinos Pastiadis · Nicole Petalidou · Ioannis Nimatoudis · Siegfried Kasper · Siegfried Kasper
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study Rebecca Schennach · Michael Riedel · Richard Musil · Michael Obermeier · Markus Jäger · Roland Bottlender · Max Schmauss · Gerd Laux · Hans-Jürgen Möller · Hans-Jürgen Möller
Treatment Options for Insomnia in Schizophrenia: A Systematic Review Pedro Oliveira · Manuel Coroa · N. Madeira · N. Madeira
Molecular Signatures of Lithium Treatment: Current Knowledge Frank Bellivier · Cynthia Marie-Claire · Cynthia Marie-Claire
Augmentation of Pharmacotherapy by Sleep Deprivation with Sleep Phase Advance in Treatment-Resistant Depression Ewa Kurczewska · Ewa Ferensztajn-Rochowiak · Anna Jasińska-Mikołajczyk · Chłopocka-Woźniak M · Janusz K. Rybakowski · Janusz K. Rybakowski
Editorial to Methamphetamine (Crystal meth) and New Psychoactive Substances Ulrich S. Zimmermann · Ulrich S. Zimmermann
Mirtazapine Induces Nightmares in Depressed Patients Jens-Armin Buschkamp · Corinna Frohn · Georg Juckel · Georg Juckel
Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms Diego Novick · William Montgomery · Tamas Treuer · Maria Victoria Moneta · Josep Maria Haro · Josep Maria Haro
Methamphetamine Consumption during Pregnancy – Effects on Child Health Jürgen Dinger · Patricia Hinner · Jörg Reichert · Mario Rüdiger · Mario Rüdiger
Evidence-Based Guidelines for the Pharmacological Management of Acute Methamphetamine-Related Disorders and Toxicity Norbert Wodarz · Anne Krampe-Scheidler · Michael Christ · Heribert Fleischmann · Winfried Looser · Katharina Schoett · Frank Vilsmeier · Lydia Bothe · Corinna Schaefer · Euphrosyne Gouzoulis-Mayfrank · Euphrosyne Gouzoulis-Mayfrank
Is Really Crocus Sativus as Effective as Citalopram in the Treatment of Depression Konstantinos N. Fountoulakis · Konstantinos N. Fountoulakis
Effects of Intramuscular Midazolam and Lorazepam on Acute Agitation in Non-Elderly Subjects – A Systematic Review Sabrina Just Kousgaard · Rasmus Wentzer Licht · René Ernst Nielsen · René Ernst Nielsen
Naming for Psychotropic Drugs: Dilemma and Challenge Hiroyuki Uchida · W. Wolfgang Fleischhacker · Georg Juckel · Gerhard Gründer · Michael Bauer · Michael Bauer
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 Christoph Hiemke · N. Bergemann · Hans Willi Clement · Andreas Conca · J. Deckert · Katharina Domschke · Gabriel Eckermann · Karin Egberts · Manfred Gerlach · C Greiner · Gerhard Gründer · Ekkehard Haen · Ursula Havemann-Reinecke · Gudrun Hefner · R. Helmer · Ger Janssen · E. Jaquenoud · Gerd Laux · Thomas Messer · Rainald Mössner · Matthias J. Müller · Michael Paulzen · Bruno Pfuhlmann · Peter Riederer · Alois Saria · B. Schoppek · Georgios Schoretsanitis · Markus J. Schwarz · M. Silva Gracia · Benedikt Stegmann · Werner Steimer · Julia C. Stingl · Manfred Uhr · S. Ulrich · Stefan Unterecker · Roland Waschgler · Gerald Zernig · G. Zurek · Pierre Baumann · Pierre Baumann
Prediction Model of Serum Lithium Concentrations Kazunari Yoshida · Hiroyuki Uchida · Hiroyuki Uchida · Takefumi Suzuki · Masahiro Watanabe · Nariyasu Yoshino · Hitoshi Houchi · Masaru Mimura · Noriyasu Fukuoka · Noriyasu Fukuoka
Driving Under the Influence of Antidepressants: A Systematic Review and Update of the Evidence of Experimental and Controlled Clinical Studies Alexander Brunnauer · Gerd Laux · Gerd Laux
Editorial to Driving Ability and Psychotropic Drugs Gerd Laux · Michael Bauer · Michael Bauer
A Systematic Review of Mechanisms of Change in Body-Oriented Yoga in Major Depressive Disorders Klara Meister · Georg Juckel · Georg Juckel
Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial Alireza Ghajar · S. M. Neishabouri · N. Velayati · L. Jahangard · N. Matinnia · M. Haghighi · A. Ghaleiha · M. Afarideh · Samrand Salimi · A. Meysamie · Shahin Akhondzadeh · Shahin Akhondzadeh
Executive Dysfunctions Predict Self-Restricted Driving Habits in Elderly People with or without Alzheimers Dementia Ilsemarie Kurzthaler · Georg Kemmler · Michaela Defrancesco · Bernadette Moser · W. Wolfgang Fleischhacker · Elisabeth M. Weiss · Elisabeth M. Weiss
Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders Dominik Wincewicz · Jan J. Braszko · Jan J. Braszko
Patients Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey Nobuhiro Nagai · Hideaki Tani · Takefumi Suzuki · Saeko Ikai · Philip Gerretsen · Masaru Mimura · Hiroyuki Uchida · Hiroyuki Uchida · Hiroyuki Uchida
The Personal Antipsychotic Choice Index Floor A. van Dijk · Iris de Wit · Matthijs Blankers · Iris Sommer · Lieuwe de Haan · Lieuwe de Haan
Influence of Long-Term Benzodiazepine use on Neurocognitive Skills Related to Driving Performance in Patient Populations: A Review Nick N. J. J. M. van der Sluiszen · Annemiek Vermeeren · Stefan Jongen · Frederick Vinckenbosch · Johannes G. Ramaekers · Johannes G. Ramaekers
Erythropoietin for Cognitive Deficits Associated with Schizophrenia, Bipolar Disorder, and Major Depression: A Systematic Review Xian-Bin Li · Wei Zheng · Yuping Ning · Dong-Bin Cai · Xin-Hu Yang · Gabor S. Ungvari · Gabor S. Ungvari · Chee H. Ng · Chuan-Yue Wang · Yu-Tao Xiang · Yu-Tao Xiang
Driving Performance of Depressed Patients who are Untreated or Receive Long-Term Antidepressant (SSRI/SNRI) Treatment Nick N. J. J. M. van der Sluiszen · Marleen Wingen · Annemiek Vermeeren · Frederick Vinckenbosch · Stefan Jongen · Johannes G. Ramaekers · Johannes G. Ramaekers
Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial Atieh Modarresi · Mehdi Sayyah · Setareh Razooghi · Kaveh Eslami · Mohammadreza Javadi · Leila Kouti · Leila Kouti
Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders Laura Albantakis · K Egberts · Rainer Burger · Christine Kulpok · Claudia Mehler-Wex · Regina Taurines · Stefan Unterecker · Christoph Wewetzer · Marcel Romanos · Manfred Gerlach · Manfred Gerlach
When the Evidence is not Enough: Commentary on Härtel-Petri et al Rebecca McKetin · Steve Allsop · Steve Allsop
Tasimelteon reentrains sleep in a patient with phase delay syndrome A. Steiger · A. Steiger
Efficacy and tolerance of a medication switch from Escitalopram to Venlafaxine in patients with Major Depressive Disorders S Wagner · S Wagner
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications Přemysl Vlček · Jakub Polák · Martin Brunovský · Jiří Horáček · Jiří Horáček
What Characterizes Depression in Old Age? Results from the Bruneck Study Michaela Defrancesco · Raimund Pechlaner · Stefan Kiechl · Johann Willeit · Eberhard A. Deisenhammer · Hartmann Hinterhuber · Gregor Rungger · Arno Gasperi · Josef Marksteiner · Josef Marksteiner
Drink and Think: Impact of Alcohol on Cognitive Functions and Dementia – Evidence of Dose-Related Effects Stefan Gutwinski · Stefanie Schreiter · Josef Priller · Jonathan Henssler · Corinde E. Wiers · Andreas Heinz · Andreas Heinz
MitoQ administration exerts anxiolytic effects in vivo Markus Nussbaumer · John M. Asara · Larysa Teplytska · M P Murphy · Alon Chen · Christoph W. Turck · Michaela D. Filiou · Michaela D. Filiou
A Critical Commentary on the 2017 AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology Jose de Leon · Jose de Leon · Jose de Leon
Consumption of Methamphetamine during Pregnancy – Transgenerational Substance Misuse? Stefan Gutwinski · Andreas Heinz · Andreas Heinz
Physical activity impacts positively on depression and objective sleep in patients with MS D Sadeghi Bahmani · M Papadimitriou · J Kesselring · J Bansi · Markus Gerber · Uwe Pühse · Edith Holsboer-Trachsler · Serge Brand · Serge Brand
Dramatic Changes Over Time of Methamphetamine Intake in a German, HIV-Positive, Sample of Men who have Sex with Men (MSM) Henrike Dirks · Stefan Esser · Norbert H. Brockmeyer · Udo Bonnet · Fabrizio Schifano · Norbert Scherbaum · Norbert Scherbaum
Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study Harris A. Eyre · Prabha Siddarth · Natalie St. Cyr · Hongyu Yang · Steve W. Cole · Steve W. Cole · Malcolm Forbes · Helen Lavretsky · Helen Lavretsky
Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings Roland Härtel-Petri · Anne Krampe-Scheidler · Wolf-Dietrich Braunwarth · Ursula Havemann-Reinecke · Peter Jeschke · Winfried Looser · Stephan Mühlig · Ingo Schäfer · Norbert Scherbaum · Lydia Bothe · Corinna Schaefer · Willem Hamdorf · Willem Hamdorf
New Psychoactive Substances (NPS) – a Challenge for the Addiction Treatment Services Norbert Scherbaum · Fabrizio Schifano · Udo Bonnet · Udo Bonnet
Restricted Elimination diet for Children with Attention-deficit/hyperactivity disorder (ADHD) I Kaiser · L Overdick · N Blazynski · C Clement · K Schneider-Momm · Hw Clement · Christian Fleischhaker · E Schulz · E Schulz
Therapeutic approaches in frontotemporal lobar degeneration – anti-tau therapy strategy in primary progressive aphasia M Otto · M Otto
Editorial to Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology Gerhard Gründer · Gerhard Gründer
New Onset of Suicidal Impulses Following Abrupt Cessation of Valproate Johannes Ladwig · Dorothea Andreae · Renate Grohmann · Sermin Toto · Stefan Kropp · Stefan Bleich · Stefan Bleich
Gearing up for the Pearl Anniversary: AGNP Set to Hold its 30th Meeting in Munich October 4–6, 2017. Overview and Abstracts Golo Kronenberg · Jens Wiltfang · Johannes Thome · Johannes Thome
Is Venlafaxine More Effective than Escitalopram and Nortriptyline in the Management of Painful Symptoms in Patients with Major Depression Jan Jaracz · Karolina Gattner · Krystyna Jaracz · Krystyna Górna · Jerzy Moczko · Joanna Hauser · Joanna Hauser
Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics Sara Baldelli · Emilio Clementi · Dario Cattaneo · Dario Cattaneo
Beta-Blockers and Evidence-Based Guidelines for the Pharmacological Management of Acute Methamphetamine-Related Disorders and Toxicity John R. Richards · John R. Richards
Lithium: An American Perspective Michael J. Gitlin · Michael J. Gitlin
Clinical Perspectives of Lithiums Neuroprotective Effect Janusz K. Rybakowski · Aleksandra Suwalska · Tomas Hajek · Tomas Hajek
Antipsychotic Treatment of 22q11.2 Deletion Syndrome-Related Psychoses Elias Angelopoulos · Christos Theleritis · Marina Economou · Korina Georgatou · Charalambos Papageorgiou · Eleftheria Tsaltas · Eleftheria Tsaltas
Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How? Rebecca Schennach · Michael Obermeier · Florian Seemüller · Markus Jäger · Max Schmauss · Gerd Laux · Herbert Pfeiffer · Dieter Naber · Lutz G. Schmidt · Wolfgang Gaebel · Joachim Klosterkötter · Isabella Heuser · Wolfgang Maier · Matthias R. Lemke · Eckart Rüther · Stefan Klingberg · Markus Gastpar · Richard Musil · Hans-Jürgen Möller · Michael Riedel · Michael Riedel
Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review Tilman Steinert · Walter Fröscher · Walter Fröscher
Driving Problems in the Elderly and Cognitively Impaired Robert Haussmann · Maria Buthut · Markus Donix · Markus Donix
Paliperidone Long-Acting Plasma Level Monitoring and a New Method of Evaluation of Clinical Stability Massimo C. Mauri · Silvia Paletta · Chiara Di Pace · Alessandra Reggiori · Chiara Rovera · Alessio Fiorentini · Carlo Altamura · Carlo Altamura
Pharmacokinetic considerations of different dosing regimens in clozapine medicated patients Georgios Schoretsanitis · Ekkehard Haen · Sarah E. Lammertz · Benedikt Stegmann · Christoph Hiemke · Maxim Kuzin · Gerhard Gründer · Michael Paulzen · Michael Paulzen
Abrupt Quitting of Long-term Heavy Recreational Cannabis Use is Not Followed by Significant Changes in Blood Pressure and Heart Rate Udo Bonnet · Udo Bonnet
Drug interactions in chronic pain disorder, addiction and affective disorder. Clinic, treatment and TDM I Adamovic · C Timäus · U Havemann-Reinecke · U Havemann-Reinecke
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin? Florian Naudet · Florian Naudet
Modulatory effects of antidepressant classes on the innate and adaptive immune system in depression Harris A. Eyre · Harris A. Eyre · Harris A. Eyre · Helen Lavretsky · J. Kartika · A. Qassim · Bernhard T. Baune · Bernhard T. Baune
Current Findings and Mechanisms of Action of Disulfiram in the Treatment of Alcohol Dependence Jochen Mutschler · Martin Grosshans · Michael Soyka · S. Rösner · S. Rösner
Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials Wei Zheng · Ying-Qiang Xiang · Chee H. Ng · Gabor S. Ungvari · Helen F.K. Chiu · Yu Tao Xiang · Yu Tao Xiang
The Effects of Antidepressants on Neuropeptide Y in Patients with Depression and Anxiety Saliha Ozsoy · O. Olguner Eker · Ummuhan Abdulrezzak · Ummuhan Abdulrezzak
Translocator Protein (TSPO) Expression in Platelets of Depressed Patients Decreases during Antidepressant Therapy Nina Sarubin · Nina Sarubin · T. C. Baghai · Juan M. Lima-Ojeda · D. Melchner · H. Hallof-Buestrich · L. Wolf · Sven Hilbert · Vladimir M. Milenkovic · Christian H. Wetzel · Rainer Rupprecht · C. Nothdurfter · C. Nothdurfter
Doxazosin, an α-1-adrenergic-receptor Antagonist, for Nightmares in Patients with Posttraumatic Stress Disorder and/or Borderline Personality Disorder: a Chart Review Stefan Roepke · Heidi Danker-Hopfe · Dimitris Repantis · Behnoush Behnia · Florian Bernard · Marie-Luise Hansen · Christian Otte · Christian Otte
Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder Nikvarz Nikvarz · Javad Alaghband-Rad · Mehdi Tehrani-Doost · Abbas Alimadadi · Padideh Ghaeli · Padideh Ghaeli
One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms A. Blázquez · Patricia Gassó · Sergi Mas · M. T. Plana · Amalia Lafuente · L. Lázaro · L. Lázaro
-759C>T Polymorphism of the HTR2C Gene is Associated with Second Generation Antipsychotic-Induced Weight Gain in Female Patients with Schizophrenia Federico Manuel Daray · Federico Manuel Daray · Demián Rodante · Laura G. Carosella · María Elena Silva · Melina Martínez · María V. Fernández Busch · D. Faccone · Rodolfo Pedro Rothlin · Paulo C. Maffía · Paulo C. Maffía
Pharmacotherapy in Children and Adolescents at Clinical-High Risk for Psychosis and Bipolar Disorder M Lambert · Niehaus · C Correll · C Correll
Neuroleptics Affect Kisspeptin mRNA Expression in the Male Rat Hypothalamus and Hippocampus Artur Pałasz · Ewa Rojczyk · A. Suszka-Świtek · Ryszard Wiaderkiewicz · Ryszard Wiaderkiewicz
Use of Paliperidone Palmitate Throughout a Schizoaffective Disorder Patients Gestation Period F. J. Zamora Rodríguez · C. Benítez Vega · M. R. Sánchez-Waisen Hernández · J. A. Guisado Macías · F.J. Vaz Leal · F.J. Vaz Leal
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-analysis – Comment to Naudet Michael Soyka · M. Friede · J. Schnitker · J. Schnitker
Treatment-resistant Schizophrenia and Global Cortical Atrophy in a Patient with Turner Syndrome S. Langgartner · Wolfgang Strube · T. Oviedo · M. Hansbauer · S. Karch · S. Wirth · Peter Falkai · Alkomiet Hasan · Alkomiet Hasan
Effects of Proton Pump Inhibitors (PPI) on the metabolism of Venlafaxine Maxim Kuzin · Sarah E. Lammertz · Benedikt Stegmann · Ekkehard Haen · Georgios Schoretsanitis · Gerhard Gründer · Michael Paulzen · Michael Paulzen
Electroconvulsive Therapy Induces Transient Sensitivity for a Serotonin Syndrome: A Case Report Michael Deuschle · Andreas Böhringer · Andreas Meyer-Lindenberg · Alexander Sartorius · Alexander Sartorius
The Relationship between Psychotropic Drug Use and Suicidal Behavior in Japan: Japanese Adverse Drug Event Report T. Takeuchi · Shinichi Takenoshita · Fumiaki Taka · Mutsuhiro Nakao · Kyoko Nomura · Kyoko Nomura
Oxytocin and Autism Spectrum Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Yoon Phaik Ooi · Shih-Jen Weng · Joe Kossowsky · Joe Kossowsky · Heike Gerger · Min Sung · Min Sung
Concurrent risperidone administration attenuates the development of locomotor sensitization following sub-chronic phencyclidine in rats Claire McKibben · Gavin P. Reynolds · Gavin P. Reynolds · Trisha A. Jenkins · Trisha A. Jenkins · Trisha A. Jenkins
Subjective Reasons for Non-Reporting of Adverse Drug Reactions in a Sample of Physicians in Outpatient Care Maximilian Gahr · Jonas Eller · Bernhard J. Connemann · Carlos Schönfeldt-Lecuona · Carlos Schönfeldt-Lecuona
Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia S. Ji · Anning Li · K. Wu · Chenhui Deng · Fang Dong · L. Li · T. Zhou · W. Yue · Chunxue Wang · Wei Lu · Wei Lu · Wei Lu
Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study M.-R. Nikbakhat · Somaye Arabzadeh · Atefeh Zeinoddini · Z. Khalili · F. Rezaei · Payam Mohammadinejad · A. Ghaleiha · Shahin Akhondzadeh · Shahin Akhondzadeh
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis Michael Soyka · M. Friede · J. Schnitker · J. Schnitker
Use of Pregabalin - A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus on Abuse Potential Ole Schjerning · Anton Pottegård · Per Damkier · Per Damkier · Mary Rosenzweig · Jimmi Nielsen · Jimmi Nielsen
The Effects of Antidepressants and Quetiapine on Heart Rate Variability Wei Lieh Huang · Shih-Cheng Liao · Terry B.J. Kuo · Terry B.J. Kuo · Li-Ren Chang · T. T. Chen · I-Ming Chen · Cheryl C.H. Yang · Cheryl C.H. Yang
Cytogenetic Effects of Chronic Methylphenidate Treatment and Chronic Social Stress in Adults with Attention-Deficit/Hyperactivity Disorder Sarah Kittel-Schneider · S. Spiegel · Tobias J. Renner · Marcel Romanos · Andreas Reif · Susanne Reichert · Julia Heupel · L. Schnetzler · H. Stopper · Christian Jacob · Christian Jacob
A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder Chee H. Ng · Chad A. Bousman · Deidre J. Smith · Nathan Dowling · Keith Byron · Joel King · Jerome Sarris · Jerome Sarris · Jerome Sarris
Association Study of 60 Candidate Genes with Antipsychotic-induced Weight Gain in Schizophrenia Patients Seunghyong Ryu · Iksoo Huh · Eun-Young Cho · Youngah Cho · Taesung Park · Se Chang Yoon · Yeon Ho Joo · K. S. Hong · K. S. Hong · K. S. Hong
Assessment of Pharmacological Treatment Quality: Comparison of Symptom-triggered vs. Fixed-schedule Alcohol Withdrawal in Clinical Practice Ulf J. Müller · F. Schuermann · Henrik Dobrowolny · Thomas Frodl · Bernhard Bogerts · S. Mohr · Johann Steiner · Johann Steiner
Conserved Hypothalamic c-Fos Activation Pattern Induced by the mGlu5 Receptor Antagonist MPEP during Peri-pubertal Development in Mice Ioana Inta · Ioana Inta · Markus Bettendorf · Peter Gass · Peter Gass
A Diet and Fitness Program Similarly Affects Weight Reduction in Schizophrenia Patients Treated with Typical or Atypical Medications Revital Amiaz · Revital Amiaz · K. Rubinstein · K. Rubinstein · Efrat Czerniak · Efrat Czerniak · Y. Karni · Mark Weiser · Mark Weiser · Mark Weiser
Azapirones for Attention Deficit Hyperactivity Disorder: A Systematic Review Yuki Matsui · Shinji Matsunaga · Yuki Matsuda · Taro Kishi · Nakao Iwata · Nakao Iwata
Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry E.J.J. Berm · Rob M. Kok · Eelko Hak · Bob Wilffert · Bob Wilffert
Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers Wei Yu · X. Sun · Yixue Li · M. Li · K. Wang · H. Li · H. Li
A Predictive Model of Plasma Lamotrigine Levels K. Kamei · Takeshi Terao · Y. Katayama · Koji Hatano · Kensuke Kodama · Masanao Shirahama · A. Sakai · Hirofumi Hirakawa · Yoshinori Mizokami · Ippei Shiotsuki · Nobuyoshi Ishii · Y. Inoue · Y. Inoue
Reversible Hypothermia in a Drug-naive Inpatient with Alzheimers Disease Receiving Pipamperone D. Kamp · M. Paschali · Christian Lange-Asschenfeldt · Christian Lange-Asschenfeldt
Nucleus Accumbens Deep Brain Stimulation for Alcohol Addiction – Safety and Clinical Long-term Results of a Pilot Trial Ulf J. Müller · Volker Sturm · Jürgen Voges · Hans-Jochen Heinze · Imke Galazky · Lars Büntjen · Marcus Heldmann · Thomas Frodl · Johann Steiner · B. Bogerts · B. Bogerts
A Case Report of a Carbamazepine Overdose With Focus on Pharmacokinetic Aspects N. Mittag · S. Meister · A. M. J. Berg · U. I. Walther · U. I. Walther
Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study M. Kellner · S. Nowack · V. Wortmann · Alexander Yassouridis · K. Wiedemann · K. Wiedemann
Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial Ladan Kashani · S. Eslatmanesh · N. Saedi · N. Niroomand · M. Ebrahimi · M. Hosseinian · T. Foroughifar · Samrand Salimi · Shahin Akhondzadeh · Shahin Akhondzadeh
Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study J. Fujioi · Kunihiro Iwamoto · Masahiro Banno · Tsutomu Kikuchi · Branko Aleksic · Norio Ozaki · Norio Ozaki
Pharmacokinetic considerations in coprescription of perazine in risperidone medicated patients Georgios Schoretsanitis · Ekkehard Haen · Sarah E. Lammertz · Benedikt Stegmann · Christoph Hiemke · Tania Veselinovic · Gerhard Gründer · Michael Paulzen · Michael Paulzen
Therapeutic Drug Monitoring in Children and Adolescents Treated with Second-Generation Antipsychotics in Daily Clinical Practice K Egberts · Sy Dang · S Fekete · C Wohkittel · L Albantakis · M Mehler-Wex · P Plener · C Wewetzer · M Romanos · M Gerlach · M Gerlach
TDM and pharmacogenetics for improving psychiatric patient care: the situation in Lausanne, Switzerland Chin B. Eap · Séverine Crettol · G Sibailly · N Ansermot · N Ansermot
TDM Update 2016 M Paulzen · M Paulzen
Drug-drug interactions in the treatment of mental disorders – from theoretical considerations to clinical practice T Messer · T Messer
The political perspective for TDM of psychoactive drugs in Europe F Bengtsson · F Bengtsson
Inter- and intraindividual variations of methylphenidate in serum and oral fluid of ADHS patients S Studer · J Preiskorn · R Lukacin · C Geffert · Christian Fleischhaker · Hw Clement · Eberhard Schulz · Eberhard Schulz
PET imaging for guiding definition of therapeutic reference ranges – new drugs, new guidelines G Gründer · G Gründer
Cytochromes P450 as paradigms of novel concepts in molecular enzymology: Multifunctional active sites and their implications in drug metabolism Wn Kühn-Velten · Wn Kühn-Velten
The Challenge of Defining Prodromal Symptoms of Schizophrenia and Bipolar Disorders B. Birmaher · B. Birmaher
Early Intervention in Psychosis and Bipolar Disorder in Children and Adolescents – Reflections on Lambert, Niehaus and Correll M Lambert · V Niehaus · C U Correll · F Schultze-Lutter · Benno G. Schimmelmann · S Ruhrmann · C Michel · S J Schmidt · A Martz-Irngartinger · P Walger · S A Hlastala · J McClellan · T Legenbauer · J Hübner · M Pinnow · C Correll · C Correll
Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy R. M. Merrill · S. M. Thygerson · C. A. Palmer · C. A. Palmer
PPAR-γ Agonists for the Treatment of Major Depression: A Review Romain Colle · D. de Larminat · Samuel Rotenberg · Franz Hozer · Patrick Hardy · Céline Verstuyft · Bruno Fève · Bruno Fève · Emmanuelle Corruble · Emmanuelle Corruble
TDM of psychotropic drugs in body fluids D Braun · B Stegmann · Ekkehard Haen · Ekkehard Haen
Effect of triglyceride and total cholesterol levels on the pharmacokinetics of clozapine in clozapine medicated patients Georgios Schoretsanitis · Sarah E. Lammertz · Christoph Hiemke · Ger Janssen · Gerhard Gründer · Michael Paulzen · Michael Paulzen
Therapeutic Drug Monitoring of Psychopharmaceuticals in Intensive Care Medicine: Two case reports of severe clozapine intoxications due to different etiologies C Müller · M Kochanek · C Tielsch · C Blaich · T Streichert · Mhj Wiesen · Mhj Wiesen
Time to Initiation of Clozapine Treatment in Children and Adolescents with Early-Onset Schizophrenia E. Trinczek · M. Heinzel-Gutenbrunner · Michael Haberhausen · Christian J. Bachmann · Christian J. Bachmann
Pharmacotherapy in Psychiatric Disorders of Children: Current Evidence and Trends M. Kölch · P. L. Plener · P. L. Plener
From Psychopharmacological Evidence to Clinical Practice: Unmet Needs in Child & Adolescent Psychiatry - Reflections on Kölch & Plener M. Holtmann · B. G. Schimmelmann · B. G. Schimmelmann
New Psychoactive Substances(NPS) A Goebel · A Goebel
Pharmacokinetic principles in the clinical practice of TDM Mj Schwarz · Mj Schwarz
Application of the AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry to patients under therapy with the antipsychotics clozapine, olanzapine, and risperidone in a community hospital in Germany D Renne · M Bürgy · E Wieland · M Shipkova · M Shipkova
TDM of psychoactive drugs in Sweden Ml Dahl · Ml Dahl
Acute urinary retention after treatment with doxepin and duloxetine I Adamovic · Renate Grohmann · E. Rüther · Detlef Degner · Detlef Degner
Serum and oral fluid concentrations of antidepressants and antipsychotics in psychiatric patients E Maurice · K Ebert · D Ebert · R Lukacin · Christian Fleischhaker · Hw Clement · Eberhard Schulz · Eberhard Schulz
Oral fluid as an alternative matrix for compliance testing in psychopharmacotherapy J Neumann · M Böttcher · M Böttcher
The clinical-pharmacological TDM report E Haen · E Haen
How to find the therapeutic reference range for psychoactive drugs C Hiemke · C Hiemke
Comparison of the pharmacokinetic interaction of antipsychotics and beta-blockers M. Silva Gracia · Regina Brandl · Ekkehard Haen · Ekkehard Haen
TDM in Italy: nobody knows A Conca · B Plattner · V Winkler · F Carpi · F Carpi
Therapeutic drug monitoring of psychotropic medication during pregnancy and lactation N Bergemann · N Bergemann
Therapeutic drug monitoring in substitution therapy Ak Laib · Ak Laib
Inter- and intraindividual variations of citalopram in serum and oral fluid of depressive patients K Ebert · J Preiskorn · D Ebert · R Lukacin · Christian Fleischhaker · Hw Clement · Eberhard Schulz · Eberhard Schulz
TDM of psychiatric drugs in the Netherlands: The wooden shoe paradigm Dj Touw · Lm Geers · Lm Geers
Analytical aspects of TDM of psychoactive drugs N von Ahsen · N von Ahsen
Quantification of 43 drugs in human serum by (U)-HPLC S Unholzer · E Haen · E Haen
Pharmacovigilance in geriatrics – pharmacological mechanisms to prevent iatrogenic cognitive decline, sedation and falls B Fay · B Fay
TDM and methylphenidate challenge Giancarlo Giupponi · I Maniscalco · A Pichler · S Holzer · Andreas Conca · Andreas Conca
High-throughput therapeutic drug monitoring (TDM) with LC-MS/MS using either manual sample preparation or fully automated on-line SPE K Kern · I Doering · I Doering
Individualizing psychopharmacological treatment – considering therapeutic drug monitoring and pharmacogenetics Stefan Unterecker · L Hommers · J. Deckert · J. Deckert
Editorial to Child and Adolescence Psychopharmacology Georg Juckel · Georg Juckel

Studies of Half-Lives of Long-Acting Antipsychotics are Needed
Pharmacopsychiatry | 2018
Georgios Schoretsanitis · Alejandro G. Villasante-Tezanos · Jose de Leon · Jose de Leon
Evaluation of Myocardial Damage After Electroconvulsive Therapy: Analyses of High-Sensitive Cardiac Troponin I and N-Terminal pro-B-type Natriuretic Peptide
Pharmacopsychiatry | 2018
Laura Kranaster · Johanna Badstübner · Suna Su Aksay · Jan Malte Bumb · Rayan Suliman · Michael Neumaier · Alexander Sartorius · Alexander Sartorius